Hutchison China MediTech Ret. on assets
What is the Ret. on assets of Hutchison China MediTech?
The Ret. on assets of Hutchison China MediTech Ltd. is -3.30%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on LSE compared to Hutchison China MediTech
What does Hutchison China MediTech do?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Companies with ret. on assets similar to Hutchison China MediTech
- Dominate has Ret. on assets of -3.31%
- Bluebird Merchant Ventures has Ret. on assets of -3.31%
- Angel Seafood has Ret. on assets of -3.31%
- Ramelius Resources has Ret. on assets of -3.31%
- Country Garden has Ret. on assets of -3.31%
- Yashili International Ltd has Ret. on assets of -3.31%
- Hutchison China MediTech has Ret. on assets of -3.30%
- PAION AG has Ret. on assets of -3.30%
- IAMGOLD has Ret. on assets of -3.30%
- Kamada Ltd has Ret. on assets of -3.30%
- Sintex Industries has Ret. on assets of -3.30%
- Kam Hing International has Ret. on assets of -3.30%
- B&G Foods, Inc has Ret. on assets of -3.30%